Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 101. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Ordinary people in extraordinary times1858
Infectious disease surveillance update1371
Chronicling PEPFAR's work in Africa960
A step forward in the journey towards hookworm vaccines783
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom702
Adaora “Ada” Alise Adimora610
Reflecting on lessons from the 2014–16 Ebola virus outbreak606
Measles immunity gaps and outbreak risk in a shifting landscape519
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7450
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis392
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations327
Correction to Lancet Infect Dis 2025; 25: e280–93301
Threat of HIV and tuberculosis drug resistance after US funding cuts301
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1293
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study266
The importance of understanding the infectious microenvironment265
Shaping opportunities for future clinical trials in tuberculosis258
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study255
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial248
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria247
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial244
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic240
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco238
Highlights from the sixth ESCMID Conference on Vaccines228
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis223
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation223
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges222
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C211
DNDi receives Dutch funding boost210
HIV vaccine trial failure208
Research in brief197
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting196
Transitioning to endemicity with COVID-19 research196
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum191
Attention to skin-related neglected tropical diseases191
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines182
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study181
Bold measures to accelerate malaria elimination178
Research in brief177
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply174
COVID-19 vaccination protects children and adolescents173
The superiority of bivalent over monovalent booster vaccines171
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations169
A patient with secondary syphilis following incomplete treatment of primary infection167
Environment and infectious diseases166
Updated criteria for paediatric sepsis and septic shock166
Surge of cutaneous leishmaniasis in Pakistan164
Infectious disease surveillance update162
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 161
Promoting diversity and equity in publishing160
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review159
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial158
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect158
Listeria monocytogenes: a rare, deadly cause of peritonitis155
The next chapter for Africa's genomic initiatives151
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin147
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study145
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial143
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden142
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study140
Mpox in people with past infection or a complete vaccination course: a global case series138
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2137
Research in brief136
Global cholera resurgence—a preventable tragedy136
Research in brief135
New flavours of tuberculosis treatment for children135
Correction to Lancet Infect Dis 2025; 25: e47–58134
Immune evasiveness of SARS-CoV-2 variants and vaccine selection129
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis128
Theresa Ochoa—staying on top of infectious diseases in Peru127
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5127
Infectious disease surveillance update126
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study126
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance126
Research in brief125
COVID-19 mortality in Africa and Asia – Authors' reply125
High-dose primaquine reduces vivax relapses: time for change124
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention123
What can be learnt from the world's first national vaccination programme against gonorrhoea123
RSV prevention: public health lessons from the southern hemisphere121
Correction to Lancet Infect Dis 2025; 25: e622121
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation118
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?117
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study115
The global burden of cryptococcosis—a neglected tropical disease?115
Correction to Lancet Infect Dis 2023; 23: e469113
Super-spreaders: a historical review111
Serpiginous-like choroiditis in ocular tuberculosis110
The response of mpox-associated inflammatory syndrome to steroid therapy109
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe107
History and evolution of tuberculosis and global health107
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis106
Tuberculosis recovery in Georgia: implementing more by 24104
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa103
Interplay of infection and vaccination in long-term protection from COVID-19103
Election of Regional Director for the Western Pacific103
Supporting healthcare access for refugees and migrants102
WHO Pathogen X conference102
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents102
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86102
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world101
0.10543203353882